BibTex RIS Cite

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

Year 2010, Volume: 13 Issue: 2, 101 - 105, 05.01.2011

H Kazancioglu Gulsum Ak

Abstract

Hemofili A erkek bebeklerin 1/5000’ini etkileyen en yaygın kalıtımsal koagülasyon bozukluğudur. Hemofili A hastalarının %25-30’unda, Hemofili B hastalarının ise %1-3’ünde yaşamları boyunca inhibitör gelişebilir. İnhibitör gelişen hemofili hastalarını tedavilerini yapmanın en etkili yol ise bu hastalara rekombinant faktör VIIa uygulanmasıdır. FVIIa plazmada pıhtının erime zamanını uzatır ve trombin ile aktive olabilen fibrinolizis inhibitörü yolu ile fibrinolizisi azaltır. Bu makalede faktör VIII’e karşı aşırı inhibitör gelişen bir hemofili hastasının yapılan başarılı dental tedavisini anlattık. rFVIIa’nın geleneksel tedavilere(örneğin faktör konsantresi) göre avantajları antijenitesinin olmaması ve viral güvenliğidir. Ancak geleneksel yöntemlere göre daha pahalı bir tedavi yöntemidir.

Keywords

-

References

  • Müftüoğlu E. Klinik Hematoloji. 4. Baskı. Diyarbakır: Şahin Yayıncılık 1995;561-7.
  • Caglar K, Cetinkaya A, Aytac S. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-8.
  • Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia ; 8: 322-29. Wilde JT. HIV and HCV coinfection in haemophilia. Haemophilia 2004; 10:1-8.
  • Bump RL, Kolodny SC. Fibrinoliysis: A possible factor in the control of postoperative hemorrhage in the patient with haemophilia. Oral Surg Oral Med Oral Pathol 1973; 36: 195-200.
  • Borea G, Hontebugnoli L, Capuzzi P, Magelli G. Tranexamic acid as a mouthwash in anticoagulant treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1993; 75: 29-31.
  • Eastmen JR, Nowakowski AR, Triplett DA. DDAVP: review of indicators for its use in the treatment of factor VIII deficiency and report of a case. Oral Surg Oral Med Oral Pathol 1983; 56: 246-51.
  • Racocz M, Mazar A, Varo D, Spierer S. Dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol 1993; 75: 280-82.
  • Katz JO, Terezhalmy GT. Dental management of the patient with haemophilia. Oral Surg Oral Med Oral Pathol 1988; 66: 139-44.
  • Manucci PH. Desmopressin (DDAVP) in the treatment of blleedin disorders: first 20 years. Blood ; 90: 2515-21.
  • Ehl S, Severin T, Sutor AH. DDAVP (desmopressin; 1-deaminocys-8-D-argine-vasopressin) treatment in children with haemophilia B. Brit J Haemathol 2000; 111: 1260-62.
  • Piot B, Sigaud M, Huet P, Fressinaud E, Trossa M, Mercier J. Management of dental extractions in patient with bleeding disorders. Oral Surg Oral Med Oral Pathol 2002; 93: 247-50.
  • High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:79-86.
  • Hoyer LW. The incidence of factor VIII inhibitors in patients with severe haemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995: 35-45.
  • Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 39.
  • Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost ; 26: 425-32. Lund-Hansen Haemostasis. 1996; 26: 96-97.
  • Negrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000; 26: 407-12.
  • Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9: –23.
  • Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. 2450/2008.0015-08. NovoSeven—virus safety. Blood Transfus ;7:24-8. DOI
  • Midathada MV, Mehta P, Waner M, Fink LM. Recombinant Factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004;121:124-137.
  • Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42.
  • Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-47.
  • Laguna P, Klukowska A. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor. Haemophilia 2005; 11: 2
  • Shapiro A. Inhibitor treatment: state of the art. Dis Mon 2003; 49: 22–38.
  • Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912–8.
  • Millar CG, Stringer MD, Sugarman I, Richards M. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171–74.
  • Janic D, Brdar R, Kristic Z, Jovanovic N, Dokmanovic L, Rodic P, Petronic I, Antovic J. Successful concurrent triple surgery in an adolescent patient with haemophilia A and inhibitors treated with recombinant factor VIIa. Haemophilia 2007; 13: 214–

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

Year 2010, Volume: 13 Issue: 2, 101 - 105, 05.01.2011

H Kazancioglu Gulsum Ak

Abstract

Hemofili A erkek bebeklerin 1/5000’ini etkileyen en yaygın kalıtımsal koagülasyon bozukluğudur. Hemofili A hastalarının %25-30’unda, Hemofili B hastalarının ise %1-3’ünde yaşamları boyunca inhibitör gelişebilir. İnhibitör gelişen hemofili hastalarını tedavilerini yapmanın en etkili yol ise bu hastalara rekombinantfaktör VIIa uygulanmasıdır. FVIIa plazmada pıhtının erime zamanını uzatır ve trombin ile aktive olabilen fibrinolizis inhibitörü yolu ile fibrinolizisi azaltır. Bu makalede faktör VIII’e karşı aşırı inhibitör gelişen bir hemofili hastasının yapılan başarılı dental tedavisini anlattık. rFVIIa’nın geleneksel tedavilere(örneğin faktör konsantresi) göre avantajları antijenitesinin olmaması ve viral güvenliğidir. Ancak geleneksel yöntemlere göre daha pahalı bir tedavi yöntemidir

Keywords

Hemofili İnhibitör rFVIIa

References

  • Müftüoğlu E. Klinik Hematoloji. 4. Baskı. Diyarbakır: Şahin Yayıncılık 1995;561-7.
  • Caglar K, Cetinkaya A, Aytac S. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-8.
  • Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia ; 8: 322-29. Wilde JT. HIV and HCV coinfection in haemophilia. Haemophilia 2004; 10:1-8.
  • Bump RL, Kolodny SC. Fibrinoliysis: A possible factor in the control of postoperative hemorrhage in the patient with haemophilia. Oral Surg Oral Med Oral Pathol 1973; 36: 195-200.
  • Borea G, Hontebugnoli L, Capuzzi P, Magelli G. Tranexamic acid as a mouthwash in anticoagulant treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1993; 75: 29-31.
  • Eastmen JR, Nowakowski AR, Triplett DA. DDAVP: review of indicators for its use in the treatment of factor VIII deficiency and report of a case. Oral Surg Oral Med Oral Pathol 1983; 56: 246-51.
  • Racocz M, Mazar A, Varo D, Spierer S. Dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol 1993; 75: 280-82.
  • Katz JO, Terezhalmy GT. Dental management of the patient with haemophilia. Oral Surg Oral Med Oral Pathol 1988; 66: 139-44.
  • Manucci PH. Desmopressin (DDAVP) in the treatment of blleedin disorders: first 20 years. Blood ; 90: 2515-21.
  • Ehl S, Severin T, Sutor AH. DDAVP (desmopressin; 1-deaminocys-8-D-argine-vasopressin) treatment in children with haemophilia B. Brit J Haemathol 2000; 111: 1260-62.
  • Piot B, Sigaud M, Huet P, Fressinaud E, Trossa M, Mercier J. Management of dental extractions in patient with bleeding disorders. Oral Surg Oral Med Oral Pathol 2002; 93: 247-50.
  • High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:79-86.
  • Hoyer LW. The incidence of factor VIII inhibitors in patients with severe haemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995: 35-45.
  • Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 39.
  • Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost ; 26: 425-32. Lund-Hansen Haemostasis. 1996; 26: 96-97.
  • Negrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000; 26: 407-12.
  • Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9: –23.
  • Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. 2450/2008.0015-08. NovoSeven—virus safety. Blood Transfus ;7:24-8. DOI
  • Midathada MV, Mehta P, Waner M, Fink LM. Recombinant Factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004;121:124-137.
  • Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42.
  • Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-47.
  • Laguna P, Klukowska A. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor. Haemophilia 2005; 11: 2
  • Shapiro A. Inhibitor treatment: state of the art. Dis Mon 2003; 49: 22–38.
  • Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912–8.
  • Millar CG, Stringer MD, Sugarman I, Richards M. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171–74.
  • Janic D, Brdar R, Kristic Z, Jovanovic N, Dokmanovic L, Rodic P, Petronic I, Antovic J. Successful concurrent triple surgery in an adolescent patient with haemophilia A and inhibitors treated with recombinant factor VIIa. Haemophilia 2007; 13: 214–
There are 26 citations in total.

Details

Primary Language English
Journal Section Original Research Articles
Authors

H Kazancioglu

Gulsum Ak

Publication Date January 5, 2011
Submission Date January 5, 2011
Published in Issue Year 2010Volume: 13 Issue: 2

Cite

EndNote Kazancioglu H, Ak G (January 1, 2011) Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı. Cumhuriyet Dental Journal 13 2 101–105.

Cumhuriyet Dental Journal (Cumhuriyet Dent J, CDJ) is the official publication of Cumhuriyet University Faculty of Dentistry. CDJ is an international journal dedicated to the latest advancement of dentistry. The aim of this journal is to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of dentistry. First issue of the Journal of Cumhuriyet University Faculty of Dentistry was published in 1998. In 2010, journal's name was changed as Cumhuriyet Dental Journal. Journal’s publication language is English.


CDJ accepts articles in English. Submitting a paper to CDJ is free of charges. In addition, CDJ has not have article processing charges.

Frequency: Four times a year (March, June, September, and December)

IMPORTANT NOTICE

All users of Cumhuriyet Dental Journal should visit to their user's home page through the "https://dergipark.org.tr/tr/user" " or "https://dergipark.org.tr/en/user" links to update their incomplete information shown in blue or yellow warnings and update their e-mail addresses and information to the DergiPark system. Otherwise, the e-mails from the journal will not be seen or fall into the SPAM folder. Please fill in all missing part in the relevant field.

Please visit journal's AUTHOR GUIDELINE to see revised policy and submission rules to be held since 2020.